New pharmacological avenues for the treatment ofl-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors

Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint

(2011) Dag Nyholm et al.   ANNALS OF NEUROLOGY

Therapies for dopaminergic-induced dyskinesias in parkinson disease

(2011) Mildred D. Gottwald et al.   ANNALS OF NEUROLOGY

Glutamate NMDA receptor dysregulation in Parkinson’s disease with dyskinesias

(2011) Imtiaz Ahmed et al.   BRAIN

Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release

(2011) O. Rascol   EUROPEAN JOURNAL OF NEUROLOGY

The Distinct Role of Medium Spiny Neurons and Cholinergic Interneurons in the D2/A2A Receptor Interaction in the Striatum: Implications for Parkinson's Disease

(2011) A. Tozzi et al.   JOURNAL OF NEUROSCIENCE

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial

(2011) Robert A Hauser et al.   LANCET NEUROLOGY

Milestones in PD genetics

(2011) Thomas Gasser et al.   MOVEMENT DISORDERS

AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials

(2011) Daniela Berg et al.   MOVEMENT DISORDERS

The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-Dopa-treated parkinsonian monkeys

(2011) Laurent Grégoire et al.   PARKINSONISM & RELATED DISORDERS

International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors--An Update

(2011) B. B. Fredholm et al.   PHARMACOLOGICAL REVIEWS

Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial

(2011) Hideyuki Sawada et al.   PLoS One

Striatal Pre- and Postsynaptic Profile of Adenosine A2A Receptor Antagonists

(2011) Marco Orru et al.   PLoS One

The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl) pyridine decreases striatal VGlut2 expression in association with an attenuation of L-dopa-induced dyskinesias

(2011) C. Marin et al.   SYNAPSE

Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-PD study

(2010) Fabrizio Stocchi et al.   ANNALS OF NEUROLOGY

An Open-Label, Positron Emission Tomography Study to Assess Adenosine A2A Brain Receptor Occupancy of Vipadenant (BIIB014) at Steady-State Levels in Healthy Male Volunteers

(2010) David J. Brooks et al.   CLINICAL NEUROPHARMACOLOGY

Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders

(2010) Robert A. Hodgson et al.   EXPERIMENTAL NEUROLOGY

Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson’s disease

(2010) Christopher Kobylecki et al.   JOURNAL OF NEUROCHEMISTRY

Quantification of Indirect Pathway Inhibition by the Adenosine A2a Antagonist SYN115 in Parkinson Disease

(2010) K. J. Black et al.   JOURNAL OF NEUROSCIENCE

Reduction of L-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease

(2010) T. H. Johnston et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

An integrated view on the role of receptor mosaics at perisynaptic level: focus on adenosine A2A, dopamine D2, cannabinoid CB1, and metabotropic glutamate mGlu5receptors

(2010) Luigi F. Agnati et al.   JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION

Long-term antidyskinetic efficacy of amantadine in Parkinson's disease

(2010) Elisabeth Wolf et al.   MOVEMENT DISORDERS

Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study

(2010) Karla Eggert et al.   MOVEMENT DISORDERS

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A randomized, controlled study

(2010) Yoshikuni Mizuno et al.   MOVEMENT DISORDERS

Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat

(2010) Manon Lebel et al.   NEUROBIOLOGY OF DISEASE

Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias

(2010) B. Ouattara et al.   NEUROSCIENCE

A long-term study of istradefylline in subjects with fluctuating Parkinson's disease

(2010) Stewart Factor et al.   PARKINSONISM & RELATED DISORDERS

Distinct Changes in cAMP and Extracellular Signal-Regulated Protein Kinase Signalling in L-DOPA-Induced Dyskinesia

(2010) Emanuela Santini et al.   PLoS One

Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian mice

(2010) Y. Ding et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily

(2009) Mikko Kuoppamäki et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Novel investigational adenosine A2Areceptor antagonists for Parkinson's disease

(2009) Annalisa Pinna   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of Movement Disorders and Depression

(2009) R. A. Hodgson et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Pharmacological Modulation of Glutamate Transmission in a Rat Model of L-DOPA-Induced Dyskinesia: Effects on Motor Behavior and Striatal Nuclear Signaling

(2009) D. Rylander et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Metabotropic glutamate receptor type 5 in levodopa-induced motor complications

(2009) Bazoumana Ouattara et al.   NEUROBIOLOGY OF AGING

Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats

(2009) N. Yamamoto et al.   NEUROSCIENCE

Pros and cons of apomorphine and l-dopa continuous infusion in advanced Parkinson's disease

(2009) Angelo Antonini et al.   PARKINSONISM & RELATED DISORDERS

Adenosine, adenosine A2A antagonists, and Parkinson's disease

(2009) P. Jenner et al.   PARKINSONISM & RELATED DISORDERS

Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial

(2009) H.H. Fernandez et al.   PARKINSONISM & RELATED DISORDERS

Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys

(2009) Marc Morissette et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)

(2008) Peter A. LeWitt et al.   ANNALS OF NEUROLOGY

Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia

(2008) Joohyung Lee et al.   BRAIN

An Update on Adenosine A2A-Dopamine D2 Receptor Interactions: Implications for the Function of G Protein-Coupled Receptors

(2008) S. Ferre et al.   CURRENT PHARMACEUTICAL DESIGN

Non-motor symptoms in Parkinson’s disease

(2008) W. Poewe   EUROPEAN JOURNAL OF NEUROLOGY

Antagonists of the Human A2AAdenosine Receptor. 4. Design, Synthesis, and Preclinical Evaluation of 7-Aryltriazolo[4,5-d]pyrimidines

(2008) Roger J. Gillespie et al.   JOURNAL OF MEDICINAL CHEMISTRY

Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease

(2008) Alim Louis Benabid et al.   LANCET NEUROLOGY

Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations

(2008) Robert A. Hauser et al.   MOVEMENT DISORDERS

Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and parkinsonism

(2008) John G. Nutt et al.   MOVEMENT DISORDERS

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

(2008) M. Stacy et al.   NEUROLOGY

Positron emission tomography analysis of [11C]KW‐6002 binding to human and rat adenosine A2Areceptors in the brain

(2008) D.J. Brooks et al.   SYNAPSE

mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys

(2007) Pershia Samadi et al.   NEUROBIOLOGY OF AGING

Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease

(2007) Giovanna Levandis et al.   NEUROBIOLOGY OF DISEASE

l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation

(2007) Barbara Picconi et al.   NEUROBIOLOGY OF DISEASE